|
Gene: ARIH2OS |
Gene summary for ARIH2OS |
Gene summary. |
Gene information | Species | Human | Gene symbol | ARIH2OS | Gene ID | 646450 |
Gene name | ARIH2 opposite strand lncRNA | |
Gene Alias | C3orf71 | |
Cytomap | 3p21.31 | |
Gene Type | ncRNA | GO ID | GO:0005575 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
646450 | ARIH2OS | HCC1_Meng | Human | Liver | HCC | 8.31e-13 | 3.18e-02 | 0.0246 |
646450 | ARIH2OS | HCC1 | Human | Liver | HCC | 8.80e-09 | 9.49e-01 | 0.5336 |
646450 | ARIH2OS | HCC2 | Human | Liver | HCC | 3.98e-14 | 1.11e+00 | 0.5341 |
646450 | ARIH2OS | HCC5 | Human | Liver | HCC | 2.07e-32 | 1.51e+00 | 0.4932 |
646450 | ARIH2OS | S014 | Human | Liver | HCC | 5.16e-06 | 2.76e-01 | 0.2254 |
646450 | ARIH2OS | S015 | Human | Liver | HCC | 1.59e-04 | 2.87e-01 | 0.2375 |
646450 | ARIH2OS | S016 | Human | Liver | HCC | 4.95e-05 | 2.48e-01 | 0.2243 |
646450 | ARIH2OS | S027 | Human | Liver | HCC | 2.92e-02 | 1.95e-01 | 0.2446 |
646450 | ARIH2OS | S028 | Human | Liver | HCC | 2.74e-06 | 2.65e-01 | 0.2503 |
646450 | ARIH2OS | S029 | Human | Liver | HCC | 1.14e-02 | 2.68e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARIH2OS | SNV | Missense_Mutation | c.414N>C | p.Leu138Phe | p.L138F | Q8N7S6 | protein_coding | tolerated_low_confidence(0.7) | possibly_damaging(0.654) | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
ARIH2OS | SNV | Missense_Mutation | c.580N>A | p.Asp194Asn | p.D194N | Q8N7S6 | protein_coding | tolerated_low_confidence(0.53) | benign(0.095) | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ARIH2OS | SNV | Missense_Mutation | novel | c.680N>G | p.Ser227Trp | p.S227W | Q8N7S6 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.913) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ARIH2OS | SNV | Missense_Mutation | c.349N>G | p.Arg117Gly | p.R117G | Q8N7S6 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.99) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ARIH2OS | SNV | Missense_Mutation | c.563G>A | p.Gly188Glu | p.G188E | Q8N7S6 | protein_coding | deleterious_low_confidence(0.05) | possibly_damaging(0.679) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ARIH2OS | insertion | Frame_Shift_Ins | rs777957265 | c.103_104insC | p.Gln35ProfsTer100 | p.Q35Pfs*100 | Q8N7S6 | protein_coding | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
ARIH2OS | SNV | Missense_Mutation | novel | c.754N>A | p.Leu252Ile | p.L252I | Q8N7S6 | protein_coding | tolerated_low_confidence(0.23) | benign(0.133) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARIH2OS | SNV | Missense_Mutation | c.818N>A | p.Ser273Asn | p.S273N | Q8N7S6 | protein_coding | tolerated_low_confidence(0.23) | benign(0.006) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARIH2OS | SNV | Missense_Mutation | c.390N>T | p.Glu130Asp | p.E130D | Q8N7S6 | protein_coding | tolerated_low_confidence(0.6) | benign(0.138) | TCGA-B5-A0JZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
ARIH2OS | SNV | Missense_Mutation | novel | c.403G>A | p.Ala135Thr | p.A135T | Q8N7S6 | protein_coding | tolerated_low_confidence(0.38) | benign(0.006) | TCGA-UB-A7MA-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Chemotherapy | gemcitabine | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |